ATE549016T1 - Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe - Google Patents

Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe

Info

Publication number
ATE549016T1
ATE549016T1 AT06740898T AT06740898T ATE549016T1 AT E549016 T1 ATE549016 T1 AT E549016T1 AT 06740898 T AT06740898 T AT 06740898T AT 06740898 T AT06740898 T AT 06740898T AT E549016 T1 ATE549016 T1 AT E549016T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
active ingredients
dissolution profiles
poorly soluble
soluble active
Prior art date
Application number
AT06740898T
Other languages
English (en)
Inventor
Huailiang Wu
Geoff Zhang
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE549016T1 publication Critical patent/ATE549016T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06740898T 2005-04-11 2006-04-11 Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe ATE549016T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67020705P 2005-04-11 2005-04-11
PCT/US2006/013651 WO2006110815A1 (en) 2005-04-11 2006-04-11 Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs

Publications (1)

Publication Number Publication Date
ATE549016T1 true ATE549016T1 (de) 2012-03-15

Family

ID=36648686

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06740898T ATE549016T1 (de) 2005-04-11 2006-04-11 Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe

Country Status (16)

Country Link
US (4) US20060228411A1 (de)
EP (2) EP2286800A1 (de)
JP (2) JP5284777B2 (de)
AT (1) ATE549016T1 (de)
CA (1) CA2603783C (de)
CY (1) CY1112980T1 (de)
DK (1) DK1868581T3 (de)
ES (1) ES2384333T3 (de)
HR (1) HRP20120502T1 (de)
ME (1) ME02003B (de)
MX (1) MX2007012642A (de)
PL (1) PL1868581T3 (de)
PT (1) PT1868581E (de)
RS (1) RS52354B (de)
SI (1) SI1868581T1 (de)
WO (1) WO2006110815A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170039758A (ko) * 2008-09-24 2017-04-11 멜린타 테라퓨틱스, 인크. 퀴놀론 화합물의 제조 방법
US20100151019A1 (en) * 2008-11-14 2010-06-17 Portola Pharmaceuticals, Inc. SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF
EP2373166A4 (de) * 2008-11-15 2014-11-05 Rib X Pharmaceuticals Inc Antimikrobielle zusammensetzungen
WO2011088152A1 (en) * 2010-01-12 2011-07-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
MY161757A (en) 2010-09-30 2017-05-15 Toyama Chemical Co Ltd Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
EP2969004B1 (de) 2013-03-15 2026-02-25 Melinta Subsidiary Corp. Delafloxacin zur verwending in der behandlung von infektionen bei adipösen patienten
CN104098548B (zh) * 2013-04-11 2017-07-18 上海医药工业研究院 一种Delafloxacin的精制方法
TWI732337B (zh) 2014-06-20 2021-07-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
TW201605447A (zh) * 2014-06-20 2016-02-16 美林塔治療學有限公司 處理感染的方法
AU2015346023A1 (en) 2014-11-14 2017-06-01 Melinta Subsidiary Corp. Method for treating, preventing, or reducing the risk of skin infection
JP7297077B2 (ja) * 2019-04-26 2023-06-23 南京中硼▲聯▼康医▲療▼科技有限公司 Ｂｐａ凍結乾燥製剤及び製造方法
CN117258513A (zh) * 2023-10-10 2023-12-22 苏州道源华智环保科技有限公司 一种复合型络合铁盐脱硫剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5221575B2 (de) * 1972-03-18 1977-06-11
DE2213275C3 (de) * 1972-03-18 1979-11-15 Desitin-Werk, Carl Klinke Gmbh, 2000 Hamburg Verfahren zur Herstellung von 5,5-Diphenylhydantoin-Natrium-Lösungen als Infusionskonzentrate
FR2525108B1 (fr) * 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
DE3420743A1 (de) * 1984-06-04 1985-12-05 Bayer Ag, 5090 Leverkusen 7-amino-1-cyclopropyl-6,8-dihalogen-1,4-dihydro-4-oxo-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
US4696814A (en) * 1985-08-21 1987-09-29 Warner-Lambert Company Parenteral phenytoin compositions
IT1207994B (it) * 1986-01-03 1989-06-01 Therapicon Srl Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
DE3626868A1 (de) * 1986-08-08 1988-02-11 Bayer Ag Parenterale loesung
AU6001790A (en) * 1989-08-02 1991-02-07 Warner-Lambert Company Formulations of phenytoin sodium for intravenous administration
JP2613139B2 (ja) * 1990-07-19 1997-05-21 エスエス製薬 株式会社 キノロンカルボン酸誘導体
GB9121316D0 (en) * 1991-10-09 1991-11-20 Wellcome Found Heterocyclic compounds
ES2160582T3 (es) * 1992-04-03 2001-11-16 Nippon Kayaku Kk Capsula dura de ocfosfato de citarabina.
DE69527617T2 (de) * 1994-04-12 2003-04-10 Arakis Ltd., Cambridge Verfahren zur racematspaltung von etodolac unter verwendung von glucamin-derivaten
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
CA2290712C (en) * 1995-09-22 2003-09-09 Wakunaga Pharmaceutical Co., Ltd. Novel pyridonecarboxylic acid derivatives or their salts, and antibacterial agents containing the same as their effective components
DK1017392T3 (da) * 1997-09-25 2002-10-21 Bayer Ag Lægemiddel
WO2001017991A1 (en) * 1999-09-02 2001-03-15 Wakunaga Pharmaceutical Co., Ltd. Quinolinecarboxylic acid derivative or its salt
EP1175205B1 (de) * 1999-11-12 2006-06-14 Abbott Laboratories Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
JP4290381B2 (ja) * 2002-04-11 2009-07-01 学校法人 聖マリアンナ医科大学 ピリドンカルボン酸化合物含有エマルション
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
EP1459739B1 (de) * 2003-03-19 2008-01-02 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Nicht-hygroskopische pharmazeutische Zusammensetzungen die nicht hydratisierte Quinolon-Carbonsäure enthalten
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
JP2005008625A (ja) * 2003-05-23 2005-01-13 Santen Pharmaceut Co Ltd キノロン系抗菌化合物を含有する点眼液
ES2901955T3 (es) * 2004-10-08 2022-03-24 Abbvie Inc Sal meglumínica y formas cristalinas de la misma de un farmaco (delafloxacina)

Also Published As

Publication number Publication date
ES2384333T3 (es) 2012-07-03
CA2603783A1 (en) 2006-10-19
RS52354B (sr) 2012-12-31
ME02003B (me) 2012-12-31
EP1868581A1 (de) 2007-12-26
JP5284777B2 (ja) 2013-09-11
US20150057266A1 (en) 2015-02-26
US20120309740A1 (en) 2012-12-06
US20100324018A1 (en) 2010-12-23
CA2603783C (en) 2014-11-18
EP1868581B1 (de) 2012-03-14
JP2008535925A (ja) 2008-09-04
US20060228411A1 (en) 2006-10-12
CY1112980T1 (el) 2016-04-13
DK1868581T3 (da) 2012-07-09
EP2286800A1 (de) 2011-02-23
HRP20120502T1 (hr) 2012-07-31
PL1868581T3 (pl) 2012-08-31
JP2013121976A (ja) 2013-06-20
PT1868581E (pt) 2012-06-22
WO2006110815A1 (en) 2006-10-19
MX2007012642A (es) 2008-01-11
SI1868581T1 (sl) 2012-06-29

Similar Documents

Publication Publication Date Title
NO20053076D0 (no) Farmasoytisk formulering med en uloselig aktiv forbindelse.
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
EP2078731A4 (de) Anti-hb-egf-antikörper als wirkstoff enthaltende pharmazeutische zusammensetzung
EP2093237A4 (de) Anti-hb-egf-antikörper als wirkstoff enthaltendes mittel für die krebstherapie
DE602004025950D1 (de) Pharmazeutische formulierung mit lanthanum-verbindungen
CR9587A (es) Derivados de piridazina
NO20075111L (no) Farmasoytisk sammensetning
ATE551989T1 (de) Kleinmolekülige heilmittelformulierung mit verzögerter freisetzung
EP1824442A4 (de) Pharmazeutische und therapeutische zusammensetzungen aus der garcinia-mangostana-l-pflanze
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
DE602004011398D1 (de) Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
ATE354362T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
CR9703A (es) Derivados de pirazolona
ATE549016T1 (de) Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe
EP2153831A4 (de) Antiermüdungsmittel und orale zusammensetzung, beide mit andrographolid als wirkstoff
EP1922025A4 (de) Arzeinmittelfreisetzendes implantat
ATE474561T1 (de) Orodispersible pharmazeutische zusammensetzung für die orale, oromukosale oder sublinguale verabreichung von agomelatin
ITMI20050729A1 (it) Nuova formulazione biologicamente attiva
ATE415949T1 (de) Pharmazeutische formulierung mit levothyroxin- natrium
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
EP1862183A4 (de) Pharmazeutische zusammensetzung mit schwer wasserlöslichem medikament
ITMI20051630A1 (it) Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi
EP1900368A4 (de) Tablette mit einem kaum löslichen wirkstoff